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Histidine-rich glycoprotein (HRG) is an abundant plasma protein with a multidomain 23 
structure allowing its interaction with many ligands including phospholipids, plasminogen, 24 
fibrinogen, IgG antibodies, and heparan sulfate. HRG has shown to regulate different 25 
biological responses such as angiogenesis, coagulation and fibrinolysis. Here, we found that 26 
HRG almost completely abrogated the infection of GHOST, Jurkat, CD4+ T cells, and 27 
macrophages by HIV-1 at low pH (range 6.5 to 5.5) but not at neutral pH. HRG was shown 28 
to interact with heparan sulfate expressed by target cells inhibiting an early post-binding 29 
step associated to HIV-1 infection. More importantly, by acting on the viral particle itself, 30 
HRG induced a deleterious effect which reduces viral infectivity. Because cervicovaginal 31 
secretions in healthy women show low pH values, even after semen deposition, our 32 
observations suggest that HRG might represent a constitutive defence mechanism in the 33 
vaginal mucosa. Of note, low pH also enabled HRG to inhibit the infection of Hep-2 cells 34 
and Vero cells by respiratory syncytial virus (RSV) and herpes simplex virus-type 2 (HSV-35 
2), respectively, suggesting that HRG might display a broad antiviral activity under acidic 36 
conditions.  IMPORTANCE. Vaginal intercourse represents a high-risk route for HIV-1 37 
transmission. The efficiency of male-to-female HIV-1 transmission has been estimated as 1 38 
in every 1,000 episodes of sexual intercourse, reflecting a high degree of protection 39 
conferred by the genital mucosa. However, the contribution of different host factors to the 40 
protection against HIV-1 at mucosal surfaces remains poorly defined. Here, we report for 41 
the first time that acidic values of pH enable the plasma protein histidine-rich glycoprotein 42 
(HRG) to strongly inhibit HIV-1 infection. Because cervicovaginal secretions usually show 43 
low pH values, our observations suggest that HRG might represent a constitutive antiviral 44 
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mechanism in the vaginal mucosa. Interestingly, infection by other viruses such as 45 
respiratory syncytial virus and herpes simplex virus-type 2 was also markedly inhibited by 46 
HRG at low pH values, suggesting that extracellular acidosis enables HRG to display a 47 
broad antiviral activity. 48 
  49 
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Histidine rich glycoprotein (HRG) is a 75 kDa single polypeptide chain protein produced 51 
by the liver (1), found at relatively high concentrations ( 150 µg/ml) in human plasma (2, 52 
3). It has a multi-domain structure (4) enabling its interaction with a variety of ligands such 53 
as phospholipids (5), plasminogen (6), fibrinogen (7), Zn
2+ 
(8), and heparan sulfate (HS) 54 
(9). HRG has been shown to modulate different biological processes including 55 
angiogenesis, cell adhesion, coagulation, and fibrinolysis (2, 10).   56 
 57 
Due to the unusually high content of histidine residues (pKa  6.5) which account for 13% 58 
of its total amino acids content (11), HRG acquires a positive net charge upon exposure to 59 
acidic environments (4). In fact, it has been proposed that HRG acts as a pH sensor, by 60 
recognizing negatively charged glycosaminoglycans (GAGs) such as HS, dermatan sulfate 61 
and chondroitin sulfate in a pH-dependent mode (12). This property of HRG might be 62 
particularly relevant in the scenario of HIV-1 infection. Heparan sulfate has shown to play 63 
an important role in sexual transmission of HIV-1 by acting as an attachment factor which 64 
contributes to the binding of the virus to vaginal epithelial cells, CD4+ T cells and 65 
macrophages (13). Moreover, it is well established that semen, the major vector of HIV-1 66 
transmission, shifts the pH of the vaginal secretions from strong acidic values (pH range 67 
3.5-5.5) (14-16) to values ranged from 6.0 to 7.0 for several hours after sexual intercourse 68 
(17, 18). Thus, we hypothesized that HRG might inhibit HIV-1 infection by preventing the 69 
interaction of HIV-1 with HS in the scenario of male to female sexual transmission of HIV-70 
1.  71 
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In this study, using different target cells and viral sources, we found that HRG almost 72 
completely abrogated HIV-1 infection at low pH values (pH range 6.5 to 5.5). We also 73 
show that the antiviral activity of HRG was not restricted to HIV-1; it effectively inhibited 74 
the infection mediated by other enveloped virus such as respiratory syncytial virus (RSV) 75 
and herpes simplex virus-type 2 (HSV-2), suggesting that HRG might display a broad 76 
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HRG strongly inhibits HIV-1 infection at low pH.  93 
We first analyzed whether HRG was able to modulate GHOST cell infection by HIV-1. In 94 
these experiments, we used GHOST cells stably transfected with CD4, CXCR4 and CCR5 95 
genes, containing a green fluorescent protein (GFP) gene under the control of a HIV-2 long 96 
terminal repeat. Cells were exposed to HIV-1 (X4 HIV-1IIIB or R5 HIV-1BAL) for 90 min at 97 
37ºC at different pH values, in the absence or presence of HRG (125 µg/ml), washed and 98 
cultured for 48 h at pH 7.3. Infection was then revealed by flow cytometry. Exposure to 99 
acidic pH values (6.5, 6.0 and 5.5) enabled HRG to strongly inhibit GHOST cell infection 100 
(Figure 1A-C), even when used at concentrations as low as 25 µg/ml (Figure 1D). No 101 
inhibition of infection was observed in cells exposed to low pH values, in the absence of 102 
HRG (Figure 1A-C). A similar inhibitory effect was found when the CD4+ T cell line 103 
Jurkat  was challenged with a GFP-encoding NL4-3 virus using either, plasma purified 104 
HRG (Figure 1E and G)  or recombinant HRG (Figure 1F). We then analyzed the 105 
antiviral effect mediated by HRG using macrophages and primary CD4+ T cells. 106 
Macrophages were obtained from monocytes isolated from peripheral blood (% purity 107 
>94%) and cultured for 5 days with GM-CSF, while CD4+ T cells were isolated from 108 
peripheral blood mononuclear cells (PBMCs) by negative selection (% purity > 95%). 109 
Macrophages were challenged with HIV-1BAL at different pH values for 90 min at 37°C, in 110 
the absence or presence of HRG. After washing, cells were cultured for 10 days at pH 7.3, 111 
and the percentage of infected cells was determined by intracellular staining of p24 using 112 
the mAb Kc-57. Consistent with the results observed in GHOST and Jurkat cells, we found 113 
that HRG strongly inhibited HIV-1 infection in macrophages challenged at low pH (Figure 114 
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1H). A similar inhibitory effect was found in activated-CD4+ T cells challenged with a 115 
GFP-encoding NL4-3 virus (Figure 1I). To confirm that inhibition of HIV-1 infection was 116 
not related to diminished cell viability induced by HRG at low pH, cell viability assays 117 
were performed. These experiments were carried out in GHOST cells, Jurkat cells, 118 
macrophages, and primary activated CD4+ T cells under similar experimental conditions 119 
than those employed in the infections assays described in Figure 1, in the absence of HIV-120 
1. Using both, an annexin-FITC/propidium iodide staining kit and a MTS assay, we found 121 
that cell exposure to low pH in the absence or presence of HRG did not compromise cell 122 
viability effect (data not shown). We conclude that extracellular acidosis enables HRG to 123 
strongly inhibit HIV-1 infection. 124 
    125 
 126 
HRG is expressed in the female reproductive tract and binds to epithelial cells, CD4+  127 
T lymphocytes and macrophages in a pH-dependent manner. 128 
HRG is produced by the liver and it can be found at high concentrations ( 150 µg/ml) in 129 
plasma. Because the tissue distribution of HRG remains largely unknown and considering 130 
that most HIV-1 transmission occurs through mucosal surfaces, we analyzed the expression 131 
of HRG at the human female reproductive tract. The squamocolumnar junction of the 132 
cervix, the ectocervix and the vagina showed an intense staining for HRG in the 133 
basal/parabasal cell layers of the epithelium. The anal canal mucosa also exhibited a high 134 
expression of HRG and as expected, a diffuse cytoplasmic staining was observed in the 135 
liver, the main source of plasma HRG (Figure 2A). These observations indicate that HRG 136 
is present at the two most frequent entry portals of HIV-1. The early attachment of HIV-1 137 
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to genital epithelial cells and CD4+ target cells is mediated by a variety of cell-surface 138 
molecules, including HS (19, 20). Previous studies performed by resonant mirror biosensor 139 
techniques have shown that HRG binding to immobilized HS is pH-sensitive, showing a 140 
maximum between 5.7 and 6.1 (12). Consistent with these observations, we found that 141 
HRG binding to the ectocervical epithelial cell line Ect1/E6E7 (Figure 2B), CD4+ T 142 
lymphocytes and macrophages (Figure 2C) showed a very strong pH-dependence; binding 143 
was negligible at pH 7.3, but markedly increased at low pH (5.5-6.5). As expected, the 144 
enhanced binding of HRG to CD4+ T cells and macrophages induced by low pH was 145 
completely prevented by heparin (Figure 2C). 146 
 147 
Low pH enables HRG to inhibit early cellular events associated with HIV-1 infection.  148 
The stratified squamous epithelium that lines the vagina and ectocervix represents an 149 
important physical barrier to incoming HIV-1(21). These cells are not susceptible to HIV-1 150 
infection but are able to bind viral particles promoting the trans-infection of CD4+ T cells 151 
and macrophages (22-24). Using the ectocervical epithelial cell line Ect1/E6E7 and the 152 
vaginal epithelial cell line VK2/E6E7, we analyzed whether HRG was capable of inhibiting 153 
early cellular events associated to the interaction between HIV-1 and genital epithelial 154 
cells. In these experiments, cells were incubated for 90 min at 37ºC at different pH values, 155 
in the absence or presence of HRG. Then, cells were extensively washed, lysed, and cell-156 
associated HIV-1 was analyzed by a p24 ELISA. Results in Figure 3A and B showed that 157 
the amount of cell-associated p24 antigen was lower in Ect1 and VK2 cells treated with 158 
HRG at low pH but not at neutral pH. Similar observations were made in cells permissive 159 
to HIV-1 infection such as activated CD4+ T cells, macrophages, Jurkat and GHOST cells 160 
(Figure 3C-F).  161 
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In order to determine whether this inhibitory effect was due to the inhibition of HIV-1 163 
binding to the cell surface, additional experiments were performed by incubating Jurkat 164 
cells for 90 min at 4°C, instead of 37ºC, in the absence or presence of HRG. Surprisingly, 165 
no inhibition of HIV-1 binding was observed (Figure 3G), suggesting that low pH enables 166 
HRG to inhibit early cellular events associated to HIV-1 infection after viral binding to the 167 
cell surface.  168 
 169 
HRG compromises viral infectivity at low pH.  170 
The results described above suggested that the inhibition of early cellular events associated 171 
to HIV-1 infection induced by HRG at low pH was dependent on the interaction of HRG 172 
with cell-associated HS. To confirm this presumption we performed additional experiments 173 
in cells lacking HS expression. GHOST cells were cultured for three days in sulfate free 174 
medium supplemented with sodium chlorate, an inhibitor of sulfation (25). Alternatively, 175 
cells were treated with heparinases I, II, and III. The results obtained (Figure 4A and B) 176 
showed that cells cultured under these conditions markedly reduced not only the expression 177 
of HS (Figure 4A), but also the enhanced binding of HRG to the cell surface observed at 178 
pH 6.0 (Figure 4B). As expected, HRG failed to inhibit the early association of HIV-1 with 179 
heparinase-treated Jurkat cells (Figure 4C), but surprisingly it was still capable of 180 
markedly inhibiting HIV-1 infection in Jurkat and GHOST cells lacking HS (Figure 4D-F).  181 
Considering that only a marginal binding of HRG was observed in target cells lacking HS, 182 
we hypothesized that the antiviral effect mediated by HRG might involve a direct action 183 
exerted on the viral particle itself. To analyze this hypothesis, HIV-1 particles were 184 
pretreated with HRG for 1 h at pH 7.3 or 6.0. Then, HRG was washed out by 185 
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ultracentrifugation and the virus was exposed to Jurkat cells, at pH 7.3 or 6.0, respectively. 186 
The results obtained showed that pretreatment of the virus with HRG at either pH 7.3 or 6.0 187 
did not exert any effect on the binding of HIV-1 to Jurkat cells (Figure 4G). By contrast, 188 
pretreatment of the virus with HRG at pH 6.0 markedly prevented the infection of Jurkat 189 
cells (Figure 4H), suggesting that low pH enables HRG to induce a deleterious effect on 190 
the viral particle.  191 
 192 
HRG interacts with HIV-1 at low pH. 193 
To analyze whether low pH values actually enabled HRG to interact with the viral particles, 194 
we performed a new set of experiments using HRG-coated beads and HIV-1 carrying Gag-195 
associated GFP (HIV NL4-3 Gag-iGFP). Validating this experimental approach, we 196 
observed that HRG efficiently bound to latex beads (Figure 5A left), and also that beads 197 
coated with the mAb 2G12 directed to gp120, but not BSA or non-specific IgG, similarly 198 
attached fluorescently labeled HIV-1 particles, at pH 7.3 and 6.0 (Figure 5A, right). We 199 
then analyzed the influence exerted by low pH on the interaction of HRG with HIV-1, and 200 
found that beads coated with plasma purified or recombinant HRG, but not with BSA or 201 
unspecific IgG, efficiently captured HIV-1 particles at low pH. We also found that heparin 202 
completely prevented HIV-1 capture by HRG-coated beads, suggesting that it involves the 203 
interaction of HRG with anionic molecules expressed on the virus surface. Interestingly, the 204 
enhanced binding of HIV-1 to HRG-coated beads observed at low pH was shown to be a 205 
reversible phenomenon. In fact, upon pH neutralization, the viral particles detached from 206 
HRG-coated beads (Figure 5B and C).  207 
 208 
HRG exerts an irreversible deleterious effect on the viral particles. 209 
 on D
ecem









Having shown that low pH enables HRG to efficiently interact with the viral surface, we 210 
then analyzed whether this interaction resulted in an irreversible loss of virus infectivity. In 211 
these experiments, HIV-1 was exposed to HRG at pH 7.3 or 6.0 for 90 min at 37°C. After 212 
this period, the viral suspension cultured with HRG at pH 6.0 was neutralized back to pH 213 
7.3. Pretreatment of HIV-1 with HRG at low pH values for 90 min did not affect the 214 
binding of virus particles to Jurkat cells (Figure 6A) but markedly reduced virus infectivity 215 
(Figure 6B). Interestingly, the antiviral effect induced by HRG was not reversed when the 216 
viral particles that had been preincubated with HRG at pH 6.0 for 90 min were further 217 
incubated for 90 or 180 min at pH 7.3, before infecting Jurkat cells. On the contrary, a 218 
progressive loss of infectivity was observed (Figure 6C).  219 
 220 
HRG displays a broad antiviral activity at low pH. 221 
We then analyzed whether low pH might enable HRG to display a broad antiviral activity. 222 
Vesicular stomatitis virus (VSV)-G pseudotyped lentivirus, represent powerful tools to 223 
study virus entry and infection in a variety of target cells due to their broad tropism (26). 224 
We first determined whether HRG inhibited the infection of Jurkat cells by VSV-G-225 
pseudotyped HIV-1 lacking gp120. HRG did not exert any inhibitory effect at pH 7.3, but 226 
markedly inhibited infection at pH values of 6.5, 6.0 and 5.5 (Fig. 7A). We also studied the 227 
effect of HRG on the infection mediated by respiratory syncytial virus (RSV). Figure 7B 228 
shows that low pH enabled HRG to prevent the infection of the epithelial cell line Hep 2 by 229 
RSV. Results depicted in Figure 7C, on the other hand, show that HRG also inhibited Vero 230 
cell infection by herpes simplex virus type 2 (HSV-2) at low pH values, although the 231 
inhibition was less pronounced compared with the observations made for HIV-1-infected 232 
cells. A strong inhibitory effect was also observed when the ectocervical epithelial cell line 233 
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Ect1/E6E7, the vaginal epithelial cell line VK2/E6E7, and the epitheloid cervix carcinoma 234 
cell line HeLa were challenged with an HSV-1 derived amplicon vector encoding GFP (27) 235 
(Figure 7D-F). Of note, results in Figure 7D and E show that HRG strongly inhibited the 236 
infection of ECT-1 and VK-2 cells at pH 7.3, suggesting that HRG might display an 237 
antiviral activity against certain virus not only at acidic values of pH, but also under neutral 238 




No previous studies have analyzed whether HRG might be able to exert any antiviral 243 
activity. Here we demonstrate that HRG strongly inhibits HIV-1 infection at low pH. HRG 244 
was shown to interact with cell HS in a pH-dependent manner, inhibiting the early 245 
association of HIV-1 with target cells. The fact that inhibition was observed at 37°C but not 246 
at 4°C, suggests that HRG inhibits a post-binding step such as virus fusion or endocytosis.  247 
Moreover, by interacting with the viral particle, HRG induced a deleterious effect which 248 
resulted in the loss of viral infectivity. Interestingly, HRG also efficiently inhibited the 249 
infection mediated by RSV and HSV-2 in cells challenged at low pH, suggesting that HRG 250 
might display a broad antiviral activity.  251 
Previous studies have shown that low pH enables HRG to mediate cytotoxic effects against 252 
fungi and bacteria (28-30). In this regard, it has been reported that HRG binds to Candida 253 
spp. inducing breaks in the cell wall and that low pH (pH 5.5) increases the membrane-254 
disrupting activitiy of HRG (29). The same authors showed that HRG preferentially lysed 255 
ergosterol-containing liposomes but not cholesterol-containing ones, suggesting that the 256 
cytotoxic effect induced by HRG might be preferentially induced on fungal but not on other 257 
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eukaryotic membranes (29). Another study from the same laboratory showed that HRG 258 
induced the lysis of the Gram-positive bacteria Enterococcus faecalis at pH 5.5, being this 259 
cytotoxic effect fully prevented by heparin (28).  260 
 261 
These microbicidal actions exerted by HRG at low pH resemble those elicited by either 262 
natural or synthetic histidine-rich peptides (31). In contrast to cationic antimicrobial 263 
peptides, histidine-rich peptides exert a bactericidal and fungicidal activity at low pH, but 264 
not at neutral pH (31). Histidines (pKa  6.5) are largely unprotonated and uncharged at 265 
neutral pH, but become protonated and positively charged at low pH. This change promotes 266 
the interaction of histidine-rich peptides with anionic lipids expressed on the surface of 267 
bacteria and fungi, thereby inducing membrane destabilization and permeabilization (29, 268 
30). The fact that bacterial and fungal membranes, but not mammalian membranes are 269 
enriched in anionic phospholipids, could explain why histidine-rich peptides are cytotoxic 270 
to bacteria and fungi (32, 33), but not to mammalian cells. Interestingly, in spite that lipids 271 
of enveloped virus are derived from the host membranes from which budding occurs, 272 
studies directed to characterize the overall lipid composition of HIV-1 particles and plasma 273 
membranes of producer cells revealed and enrichment of cholesterol and sphingomyelin in 274 
the virus (34, 35). Moreover, mature virions express phosphatidylserine (PS) and 275 
phosphatidylethanolamine (PE) on their external surface, indicating that virus membrane 276 
does not retain the asymmetric lipid distribution of host producer cells (35). These 277 
differences could explain why HRG exerts a deleterious effect on viral particles but not on 278 
target cells. A limitation of our study is that the association of HRG with HIV-1 and the 279 
subsequent loss of viral infectivity were only analyzed in viruses produced by 293T cells, 280 
and not in those produced by T cells or macrophages, which might differ in both, the host 281 
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cell factors expressed at the viral surface and its ability to bind HRG. Further studies are 282 
needed to determine whether a similar mechanism accounts for the inhibition of HIV-1 283 
infection mediated by HRG in CD4+ T cells and macrophages.  284 
 285 
Interestingly, not only low pH but also Zn
2+
 is able to impose a positive charge to the 286 
histidine-rich domain of HRG (1, 8). In fact, the ability of HRG to interact with cell-287 
surface-HS at neutral pH markedly increases following the interaction of HRG with Zn
2+
, at 288 
physiological concentrations of Zn
2+
 (10-20 M) (9). We speculate that Zn
2+
 might enable 289 
HRG to exert an antiviral effect at neutral pH. This hypothesis, however, should be 290 
rigorously tested because most of Zn
2+
 is tightly bound to plasma proteins reducing free 291 
Zn
2+
 concentrations from micromolar to nanomolar levels (36). Interestingly, it has been 292 





Since platelets exert antiviral effects (38, 39), we surmise that 294 
platelet´s activation and degranulation might enable HRG to inhibit viral infections in a 295 
Zn
2+
-dependent mode. Further studies are required to test this possibility. 296 
 297 
We also found that low pH enhanced the binding of HIV-1 to the epithelial cell lines Ect1 298 
and VK2. Interestingly, we have previously reported that HIV-1 binding to spermatozoa, 299 
but no to CD4+ T cells or dendritic cells, was markedly increased at pH 6.0 or pH 6.5, 300 
compared with neutral pH (40). Because HS plays a major role in the binding of HIV-1 to 301 
epithelial cells (20) we surmise that low pH might increase the affinity of the envelope 302 
glycoprotein gp120 or any of the host-derived proteins which are incorporated to the virus 303 
during the budding process(41, 42) to HS via protonation of histidine residues. In fact, low 304 
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pH values in the range 6.0-7.0 have shown to increase the binding of a number of proteins 305 
such as the gp64 of baculovirus, prion protein, selenoprotein P, GM-CSF, VEGF, and the 306 
non-fibrillar form of beta-amyloid peptide to HS via protonation of histidine residues (43, 307 
44). Further studies are required to test this hypothesis.  308 
 309 
No previous studies have analyzed the presence and the role of HRG at mucosal surfaces, 310 
the first entry portals for many infectious agents. We found that HRG is present in the 311 
basal/parabasal cell layers of the ectocervix and vaginal epithelium, as well as in the anal 312 
canal mucosa. Whether or not this reflects a local production of HRG remains to be 313 
determined.  Besides this, considering the high concentrations of plasma HRG ( 150 314 
g/ml) we speculate that microabrasions of the mucosal surface induced either by genital 315 
ulcer diseases or mechanical stress during intercourse might contribute to increase the local 316 
concentration of HRG. It is of note that this is not an unusual scenario; in fact, epithelial 317 
microabrasions of the vaginal mucosa are usually detected in 60% of healthy women after 318 
consensual intercourse (45). A limitation of our study is the lack of data proving that the 319 
HRG concentration present at the cervicovaginal tissues is capable of exerting its anti-viral 320 
effect in vivo. Further studies in HRG knockout mice are required to assess this. 321 
These observations places HRG at the female reproductive tract and since the 322 
cervicovaginal fluids in healthy women show low pH values (14, 15), even after semen 323 
deposition (17, 18, 46), we surmise that HRG might exert a protective role against sexually 324 
transmitted virus such as HIV-1. It should be emphasized that the antiviral activity of the 325 
HRG might not be limited to the female reproductive tract since mucosal surfaces from 326 
other tissues such as the urinary, the gastrointestinal and the respiratory tracts, are usually 327 
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exposed to low pH values too (14, 47-49). Different studies have shown that, even in the 328 
absence of inflammatory processes, the pH of the airway surface liquid (ASL), a thin (25 329 
µm) layer of fluid that coats the airway mucosal surface, is acidic due to a constitutive and 330 
amiloride-sensitive process of proton secretion by the airway epithelium, which is further 331 
activated during airway inflammation (50, 51). The intraluminal pH gradient along the 332 
gastrointestinal tract shows acidic pH values in the small intestine (pH 6.0–7.4) and the 333 
caecum (pH 5.7) (52-54). Not only mucosal surfaces, but also the skin surface is acidic in a 334 
range from pH 4.0 to 6.0 (55). This acid mantle strongly contributes to the barrier function 335 
of the skin by preventing infection by bacteria, fungi, and virus (56). Furthermore, is even 336 
possible that HRG could exert an antiviral activity at neutral pH since the infection of the 337 
vaginal and ectocervical epithelial cell lines VK2/E6E7 and Ect1/E6E7 by an HSV-1 338 
derived amplicon was markedly inhibited not only at low pH, but also at neutral pH. 339 
Further studies are required to determine the relevance of this observation as well as the 340 
mechanisms through which HRG might display an antiviral activity at neutral pH values.  341 
 Together, our observations suggest that HRG might display an antiviral activity at the 342 
major portals of entry for infectious pathogens.  343 
 344 
  345 
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MATERIALS AND METHODS 346 
Ethics statement. The institutional review board of the “Hospital Italiano” (Buenos Aires, 347 
Argentina) approved the study. All blood donors provided written informed consent. 348 
 349 
HRG purification.  HRG was purified from healthy plasma donors (“Hospital Mendez”, 350 
Buenos Aires, Argentina), as previously described (57).  Briefly, human plasma was loaded 351 
into chromatography columns containing Ni-NTA agarose (Qiagen) and incubated at 4°C 352 
in agitation for 1 h. After plasma elution, weakly bound contaminant material was removed 353 
with a series of increasing imidazole concentrations; 5 mM, 20 mM and 100 mM in TBS, 354 
pH 8,0. HRG was then eluted with a 250 mM imidazole solution, extensively dialyzed 355 
against PBS and frozen at -80°C. HRG concentration was assessed by ELISA (Sino 356 
Biological).  357 
 358 
Cells, plasmids and viral stocks. PBMCs were isolated from healthy volunteers (“Hospital 359 
Mendez”, Buenos Aires, Argentina), by standard density gradient centrifugation on Ficoll-360 
Hypaque. Monocytes were obtained using CD14 microbeads (Miltenyi Biotec). The purity 361 
was checked by FACS analysis using a mAb directed to CD14 and was found to be >94%. 362 
To obtain macrophages, monocytes were suspended in RPMI 1640 medium (GIBCO) and 363 
adhered for 1 h to flat-bottom 24-multiwell plates, afterwards cells were cultured in 364 
medium supplemented with 10% fetal bovine serum (GIBCO) and 40ng/ml of GM-CSF 365 
(Miltenyi Biotec) for 6 days. CD4+ T cells were isolated from PBMCs by negative 366 
selection, using a CD4 + T-cell Isolation Kit (Miltenyi Biotec) (purity > 95%). Cells were 367 
activated for 3 days with anti-CD3/CD28 beads (Miltenyi Biotec) in 10 U/ml of IL-2 368 
supplemented culture medium.  369 
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The osteosarcoma cell line GHOST, stably transfected with CD4, CXCR4 and CCR5 genes 370 
and cotransfected with the HIV-2 long terminal repeat driving a EGFP construct which 371 
transcribes upon HIV-1 DNA integration with the cellular DNA, was obtained from the 372 
AIDS Reagent Program, Division of AIDS, NIAID, NIH. The clone E6-1 of the human 373 
CD4+ T cell line Jurkat, the neoplastic cell line H9 infected by HIV-1IIIB, the HIV-1BaL 374 
strain and the HIV-1 vector plasmid pNL4-3, were obtained from the AIDS Reagent 375 
Program. The HIV-1 pUC-NL4-3 Gag internal GFP was obtained from Michael Schindler 376 
(Institute of Virology, Munich, Germany). The pCMV-VSV-G was obtained from Addgene 377 
(Sydney, Australia). The pBR-NL4.3-IRES-eGFP-nef+ encoding full-length HIV-1 in the 378 
pBR322 backbone under the control of viral long terminal repeat promoter was kindly 379 
provided by F. Kirchhoff (Institute of Molecular Virology, Ulm University Medical Center, 380 
Ulm, Germany). 381 
 382 
Vero, VK2/E6E7, Ect1/E6E7, and HEp-2 cells were purchased from ATCC and cultured 383 
according to the manufacturer's instructions. HIV-1 NL4-3, HIV-1 NL4-3-EGFP, HIV-1 384 
NL4-3 Gag-iGFP and the VSV-G pseudotyped Env-EGFP NL4-3 viral stocks were 385 
obtained transfecting HEK 293T cells, as previously described (58, 59). The HIV-1IIIB viral 386 
stock was obtained from H9 supernatants, as previously described (60). The HIV-1Bal strain 387 
was amplified in monocyte-derived macrophages. In all cases, cell supernatants were 388 
filtered through a 0.45-micron filter and concentrated by ultracentrifugation at 28 000 rpm 389 
for 90 min at 4°C (L7-65 ultracentrifuge; Beckman Coulter). The G-strain of HSV-2 was a 390 
gift from C. Pujol (University of Buenos Aires, Argentina). HSV-2 was propagated and 391 
titrated in Vero cells as described previously (61), and the infectious titer was expressed as 392 
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plaque forming units (pfu) per ml. The HSV-1 derived amplicon vector encoding GFP was 393 
kindly provided by D. Jerusalinsky (University of Buenos Aires, Argentina) and A. L. 394 
Epstein (Université Claude Bernard Lyon, Villeurbanne, France). The RSV subtype A, 395 
strain Long was a kind gift from Elsa Baumeister (Malbrán Institute, Argentina). 396 
 397 
Infection assays. Infection of CD4+CXCR4+CCR5+GHOST cells was performed as 398 
described (4). Briefly, 12000 GHOST cells were plated in 24 flat-bottom multiwell plates, 399 
in a final volume of 400 µl/well (RPMI medium supplemented with 10% fetal calf serum) 400 
on day 0. The next day, cells were washed and challenged with HIV-1 (X4 HIV-1IIIB or R5 401 
HIV-1BAL, 10 ng of p24/well) for 90 min at 37ºC, in the absence or presence of HRG (125 402 
µg/ml), at different pH values. After 90 min of incubation at 37ºC, cells were washed and 403 
cultured at pH 7.3 for 72 h. Then, infection was analyzed by flow cytometry. Jurkat cells 404 
and anti-CD3/CD28 activated CD4+ T cells were incubated in 96 U-bottom well plates at 405 
concentrations or 30000 cells/well/100 µl and 100000 cells/well/100 µl, respectively. Jurkat 406 
and CD4+ T cells were challenged with X4 HIV-1 NL4-3 EGFP virus (10ng p24/well and 407 
50ng p24/well, respectively) for 90 min at 37°C, in the absence or presence of HRG (125 408 
µg/ml), at different pH values. Then, cells were washed, cultured for 3 or 5 days at pH 7.3, 409 
and infection was revealed by flow cytometry. Macrophages were cultured in 24 flat-410 
bottom multiwell plates (350000 cells/well/350 µl) and infected with HIV-1BAL (50ng 411 
p24/well) at different pH values, in the absence or presence of HRG (125 µg/ml), for 90 412 
min at 37°C. After washing with culture medium, macrophages were cultured for 10 days 413 
at pH 7.3, and the percentage of infected cells was determined by intracellular staining of 414 
p24 with the mAb Kc-57 (Beckman-Coulter). Vero cells were plated to 80% confluence in 415 
24 flat-bottom  multiwell plates, and challenged with a pre-titered amount of HSV-2 for 90 416 
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min at 37ºC, in the absence or presence of HRG (125 g/ml), at different pH values. Then, 417 
cells were washed with PBS twice and cultured at pH 7.3 for 72 h at 37°C. Infection was 418 
evaluated by determining the number of pfu/well. Ect1/E6E7, VK2/E6E7 and HeLa cells 419 
were plated to 80% confluence in flat-bottom 24 multiwells plates and challenged with a 420 
pre-titered amount of HSV-1 derived amplicon vector encoding GFP, in the presence or 421 
absence of HRG (125 µg/ml), for 90 min at 37°C, at different pH values. Then, cells were 422 
washed with PBS twice and cultured at pH 7.3, for 72 h at 37°C. Cells were harvested and 423 
analyzed by flow cytometry. HEp-2 cells (50% confluence) were challenged with RSV 424 
(MOI 0.5), in the presence or absence of HRG (125 µg/ml), for 90 min at 37°C, at different 425 
pH values. Cells were then washed twice and cultured for at pH 7.3 for 3 days in 48-well 426 
plates in culture medium supplemented with 2% FCS. Next, cells were harvested, and the 427 
expression of viral antigen was detected by intracellular staining and flow cytometry, using 428 
a mouse anti-human RSV mAb (EMD Millipore Corporation) and a PE-goat anti-mouse-429 
IgG (Dako). 430 
 431 
Cell viability assays. Apoptosis and necrosis was evaluated by staining with annexin-432 
FITC/propidium iodide (BD Biosciences) and flow cytometry. Cells were labeled with 433 
annexin-V FITC and propidium iodide for 15 min at room temperature and analyzed by 434 
flow cytometry using a BD FACSCanto cytometer and BD FACSDiva software (BD 435 
Biosciences). Cell viability was also assessed by using the MTS assay (Abcam), based on 436 














HRG binding to target cells. Ect1/E6E7 cells, CD4+ T cells and macrophages, were 440 
incubated at 4°C for 1 h, in the absence or presence of different concentrations of HRG, at 441 
pH values of 7.3, 6.5, 6.0, or 5.5. After washing, bound HRG was revealed by flow 442 
cytometry using a mouse mAb anti-HRG (Sino Biological), and an Alexa-488 anti mouse 443 
mAb (Jackson Immuno Research).  444 
 445 
HIV-1 attachment to target cells. The cell lines Ect1/E6E7, VK2/E6E7, Jurkat, GHOST, 446 
activated-CD4+ T cells and macrophages were incubated with HIV-1IIIB or HIV-1 NL4-3 447 
(50ng of p24/well), for 90 min at 37°C with HRG (125 µg/ml) at different pH values. In all 448 
cases, cells were washed 5 times with PBS,  lysed using RIPA lysis buffer and the amount 449 
of p24 was evaluated as absorbance at 450 nm, using Genscreen ULTRA HIV Ag-Ab (Bio-450 
Rad). 451 
 452 
Heparan sulfate removal from target cells. To abrogate HS synthesis, GHOST cells 453 
where cultured for 36 h with 25 mM of sodium chlorate in a custom made DMEM medium 454 
lacking sulfate, supplemented with 10% of fetal calf  serum, as described (25). For 455 
enzymatic removal of HS, Jurkat and GHOST cells were treated with 5 mIU/ml of a 456 
heparinase I and III blend (Sigma)  and 5 mIU/ml of heparinase II (Sigma), for 1h at 37°C. 457 
 458 
HRG binding to HIV-1. Aldehyde/Sulfate Latex beads (Molecular Probes) were coated 459 
with purified HRG, recombinant HRG (Sino Biological), bovine serum albumin (Sigma-460 
Aldrich), human IgG (Sigma-Aldrich) or the anti-gp120 mAb 2G12 (AIDS Reagent 461 
Program), following the manufacturer's instructions. Briefly, 70 µg of each protein, 462 
previously dialyzed against MES buffer 0.025 M, pH 6, were added to 1x10
8
 beads that had 463 
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already been washed and suspended in MES buffer. After overnight incubation under 464 
rotation at room temperature, beads were extensively washed with a PBS-BSA 2 % 465 
solution and stored at 4°C in PBS with 0,1% glycine and 0,1% sodium azide. HIV-1 466 
capture assays were performed as follows. 1500-2000 beads were incubated with the HIV-1 467 
NL4-3 Gag-iGFP virus (10 ng of p24), at different pH values, at 37°C for 45min under 468 
agitation. Then, the attachment of GFP-virus to latex beads was evaluated by flow 469 
cytometry.  470 
Immunohistochemistry. Paraffin blocks of human liver, cervix, vagina and anus were 471 
retrieved from the surgical archives of the Pathology Department of the Italian Hospital, 472 
Buenos Aires, Argentina. Paraffin immunohistochemistry was performed using a 473 
monoclonal anti-HRG antibody (Sino Biological ) at 1:75 dilution. Briefly, four-micron 474 
thick sections of paraffin-embedded tissue blocks were baked for at least 30 min in an oven 475 
at 60°C. Deparaffinization, antigen retrieval, blockage of endogenous peroxidase activity, 476 
peroxidase–labeled anti-mouse IgG dispense and incubation steps were all performed on 477 
automated XT Benchmark Instrument (Ventana, Tucson, AZ, USA). Next, the slides were 478 
removed from the instrument after completion of the run, dipped 10–15 times in water to 479 
remove the oil, rinsed in tap water, dehydrated using a graded series of reagent alcohols, 480 
dipped in xylene and coverslipped for microscopic examination.  481 
 482 
Statistics. Data are shown as mean values ± SEM. Student paired t-test was used to 483 
determine the significance of differences between treatment groups. Multiple analyses were 484 
followed by Bonferroni’s multiple-comparison posttest. The p values <0.05 were 485 
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Figure legends. 643 
Figure 1: HRG inhibits HIV-1 infection at low pH values. A-C. HIV-1 infection was 644 
assessed using the reporter cell line GHOST transfected with CD4, CXCR4 and CCR5 645 
genes. Cells were challenged with HIV-1IIIB or HIV-1BAL strains (10 ng of p24/well) for 90 646 
min at 37ºC, in the absence or presence of HRG (125 µg/ml), at different pH values. Cells 647 
were then washed and cultured for 72 h at pH 7.3, and infection was revealed by flow 648 
cytometry. D. GHOST cells were challenged with HIV-1IIIB  (10 ng of p24/well) for 90 min 649 
at 37ºC at pH 7.3 or 6.0, in the absence or presence of different concentrations of HRG. 650 
Cells were then washed and cultured for 72 h at pH 7.3, and infection was revealed by flow 651 
cytometry.  E and F. Jurkat cells were challenged with HIV-1 NL4-3-EGFP (10 ng of 652 
p24/well) for 90 min at 37ºC, in the absence or presence of plasma purified (E) or 653 
recombinant HRG (125 g/ml) (F), at different pH values. Cells were then washed and 654 
cultured for 3 or 5 days at pH 7.3, and infection was revealed by flow cytometry. (G) Jurkat 655 
cells were challenged with HIV-1 NL4-3-EGFP (10 ng of p24/well) for 90 min at 37ºC, in 656 
the absence or presence of different concentrations of plasma purified HRG, at pH 7.3 or 657 
6.0. Cells were then washed and cultured for 5 days at pH 7.3, and infection was revealed 658 
by flow cytometry. H. Monocyte-derived macrophages were challenged with HIV-1BAL (50 659 
ng of p24/well) for 90 min at 37ºC, in the absence or presence of HRG (125 µg/ml), at 660 
different pH values. Cells were then washed and cultured for 10 days at pH 7.3. Infection 661 
was then revealed by intracelular staining of p24 antigen with the mAb Kc-57 and flow 662 
cytometry. I. Purified CD4+ T cells were activated for 3 days with anti-CD3/CD28 coated 663 
beads in the presence of IL-2 (10 U/ml). Cells were challenged with HIV-1 NL4-3-EGFP 664 
(50 ng of p24/well) for 90 min at 37ºC in the absence or presence of HRG (125 µg/ml), at 665 
different pH values. Then, cells were washed and cultured for 6 days at pH 7.3, and 666 
infection was revealed by flow cytometry. A, D and G: representative experiments (n4-8) 667 
are shown. B, C, E and F-I: results are expressed as the mean ± SEM of 4-8 experiments. 668 













Figure 2. HRG is expressed at the female reproductive tract and binds to cells in a 671 
pH-dependent manner. (A). HRG expression was studied by immunohistochemistry in 672 
the female reproductive tract and anal canal. The squamocolumnar junction of the cervix, 673 
the ectocervix, the vagina and the anal canal show an intense staining for HRG in the 674 
basal/parabasal cell layers of the epithelium. A diffuse cytoplasmic staining was observed 675 
in the liver. C and D. Ect1/E6E7 cells, CD4+ T cells previously activated during 3 days 676 
with anti-CD3/CD28 coated beads, and macrophages were incubated with HRG (125 677 
µg/ml) at different pH values for 1 hour at 4ºC, and the binding of HRG to the cell surface 678 
was then evaluated  by flow cytometry.  C and D. Representative experiments are shown (n 679 
= 3). *p < 0.01 vs cells incubated without HRG.   680 
 681 
Figure 3. HRG inhibits early cellular events associated with HIV-1 infection. 682 
Experiments were performed by incubating (90 min at 37°C) Ect1/E6E7 cells (A), 683 
VK2/E6E7 cells (B), anti-CD3/anti-CD28 activated CD4+ T cells (C), macrophages (D), 684 
Jurkat (E) and GHOST cells (F), with  NL4-3 HIV-1 (50 ng of p24/well), at different pH 685 
values, in the absence or presence of HRG (125 µg/ml). Then, cells were extensively 686 
washed and lysed using RIPA lysis buffer and the concentration of p24 was evaluated by 687 
ELISA as absorbance at 450 nm. G. Jurkat cells were incubated for 90 min at 37°C or 4ºC 688 
with NL4-3 HIV-1 (50 ng of p24/well), at different pH values, in the absence or presence of 689 
HRG (125 µg/ml). Then, cells were extensively washed and lysed using RIPA lysis buffer 690 
and the concentration of p24 was evaluated by ELISA as absorbance at 450 nm. Results are 691 
expressed as the mean ± SEM of 4-5 experiments. *p < 0.01 vs cell incubated without 692 
HRG.  693 
 694 
Figure 4. Analysis of the mechanisms through which HRG inhibits HIV-1 infection. 695 
 (A) GHOST cells were grown during three days in control medium or in sulfate free 696 
medium supplemented with sodium chlorate (25mM) (left) or treated with heparinases I, II, 697 
and III (5 mIU/ml) during 90 min at 37°C (right). Then, the expression of HS was 698 
evaluated by flow cytometry. (B) GHOST cells were treated as described in (A). Then, 699 
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HRG binding assays were performed by incubating cells with HRG (125 µg/ml) at pH 7.3 700 
or 6.0, for 60 min at 4ºC. HRG binding was then revealed by flow cytometry. (C) Untreated 701 
(controls) or heparinase-treated Jurkat cells were incubated for 90 min at 37°C with NL4-3 702 
HIV-1 (50 ng of p24/well), at different pH values, in the absence or presence of HRG (125 703 
µg/ml). Then, cells were extensively washed and lysed using RIPA lysis buffer and the 704 
concentration of p24 was evaluated by ELISA as absorbance at 450 nm. (D) Untreated or 705 
heparinase-treated Jurkat cells were challenged with HIV-1 NL4-3-EGFP (10 ng of 706 
p24/well) for 90 min at 37ºC, in the absence or presence of HRG (125 µg/ml), at pH 7.3 or 707 
6.0. Cells were then washed, and infection was revealed by flow cytometry after 5 days of 708 
culture at pH 7.3. E and F. GHOST cells were treated as described in (A). Then, cells were 709 
challenged with HIV-1 NL4-3 (10 ng of p24/well) for 90 min at 37°C, at pH 7.3 or 6.0, in 710 
the absence or presence of HRG (125 µg/ml). Cells were then washed and cultured for 72 h 711 
at pH 7.3, and infection was revealed by flow cytometry. (G) HIV-1 NL4-3 (50 ng of 712 
p24/well) was preincubated, or not, with 125µg/ml of HRG at pH 7.3 or 6.0, for 90 min at 713 
37°C. After this period, the viral suspension was centrifuged twice to wash out HRG, and 714 
resuspended in culture medium at pH 7.3 or pH 6.0, respectively. Then, Jurkat cells were 715 
exposed to these viral suspensions for 90 min at 4°C, washed, lysed with RIPA lysing 716 
buffer, and the amount of p24 antigen was evaluated by ELISA as absorbance at 450 nm. 717 
(H). HIV-1 NL4-3-EGFP (10 ng of p24/well) was preincubated, or not, with 125µg/ml of 718 
HRG at pH 7.3 or 6.0, for 90 min at 37°C. After this period, the viral suspension was 719 
centrifuged twice to wash out HRG, and resuspended in culture medium at pH 7.3 or pH 720 
6.0, respectively. Then, Jurkat cells were exposed to these viral suspensions for 90 min at 721 
37°C, at pH 7.3 or 6.0. Cells were washed, and cultured for 3 days at pH 7.3, and infection 722 
was revealed by flow cytometry. Representative experiments (n = 3) are shown in (A) and 723 
(B). In C-H, results are expressed as the mean ± SEM of 3-5 experiments. *p < 0.01, 724 
control vs HRG. 725 
 726 
Figure 5. Low pH enables HRG to interact with HIV-1. A, left. HRG-coated latex beads 727 
were analyzed by flow cytometry using a mouse IgG mAb anti-HRG and a FITC-IgG anti-728 
mouse IgG. BSA-coated latex beads were used as controls. A, right. Latex beads coated 729 
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with BSA or the anti-gp120 mAb 2G12, were incubated for 45 min at 37°C under agitation 730 
with HIV-1 NL4-3 Gag-iGFP virus (10 ng of p24), at pH 7.3 or 6.0. Then, HIV-1 capture 731 
by latex beads was analyzed by flow cytometry. B and C. Latex beads coated with BSA, 732 
nonspecific IgG, purified HRG or recombinant HRG, were incubated for 45 min at 37°C 733 
under agitation with HIV-1 NL4-3 Gag-iGFP virus (10 ng of p24), at pH 7.3 or 6.0. Then, 734 
HIV-1 capture by latex beads was analyzed by flow cytometry. When indicated, heparin 735 
(50 U/ml) was added during the capture assay. In experiments directed to analyze the 736 
reversibility of HIV-1 association with HRG, latex beads coated with purified HRG were 737 
incubated for 45 min at 37°C with HIV-1 NL4-3 Gag-iGFP virus (10 ng of p24) at pH 6.0. 738 
Then, the pH was corrected, or not, to 7.3, and the beads was incubated for an additional 739 
period of 45 min at 37°C. Then, HIV-1 capture by latex beads was analyzed by flow 740 
cytometry. Representative experiments (n = 3-5) are shown. 741 
 742 
Figure 6. HRG exerts an irreversible deleterious effect on the viral particles. (A) HIV-743 
1 NL4-3-EGFP (10 ng of p24/well) was preincubated, or not, with 125µg/ml of HRG at pH 744 
7.3 or 6.0, for 90 min at 37°C. After this period, the viral suspension cultured with HRG at 745 
pH 6.0 was neutralized back to pH 7.3. Then, Jurkat cells were exposed to these viral 746 
suspensions for 90 min at 4°C, washed, lysed with RIPA lysing buffer, and the amount of 747 
p24 antigen was evaluated by ELISA as absorbance at 450 nm. (B) HIV-1 NL4-3-EGFP 748 
(10 ng of p24/well) was preincubated, or not, with 125µg/ml of HRG at pH 7.3 or 6.0, for 749 
90 min at 37°C. After this period, the viral suspension cultured with HRG at pH 6.0 was 750 
neutralized back to pH 7.3. Then, Jurkat cells were exposed to these viral suspensions for 751 
90 min at 37°C, at pH 7.3. Cells were washed, and cultured for 3 days at pH 7.3, and 752 
infection was revealed by flow cytometry. (C) HIV-1 NL4-3-EGFP (10 ng of p24/well) 753 
was preincubated, or not, with 125µg/ml of HRG at pH 6.0, for 90 min at 37°C. Then, the 754 
pH was neutralized back to pH 7.3, and Jurkat cells were exposed to these viral suspensions 755 
for 90 min at 37°C and pH 7.3, immediately or after further incubation at pH 7.3 of the 756 
viral suspensions for 90 min and 180 min. Then, cells were washed, and cultured for 3 days 757 
at pH 7.3, and the infection was revealed by flow cytometry. Results are expressed as the 758 
mean ± SEM of 4-5 experiments. *p < 0.01 vs cell incubated without HRG. 759 
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Figure 7. Low pH enables HRG to display a broad antiviral activity. (A) Jurkat cells 760 
were challenged with VSV-G pseudotyped NL4-3 ΔEnv-EGFP (10 ng p24/well) for 90 min 761 
at 37ºC, in the absence or presence of HRG (125 µg/ml), at different pH values. Cells were 762 
then washed, cultured for 5 days at pH 7.3, and infection was revealed by flow cytometry. 763 
(B). Hep-2 cells (50% confluence) were challenged with a pre-titered amount of RSV for 764 
90 min at 37°C, in the absence or presence of HRG (125 µg/ml), at different pH values. 765 
Cells were then washed, cultured for 3 days at pH 7.3, and infection was revealed by flow 766 
cytometry. C. Vero cells (80% confluence) were challenged with a pre-titered of HSV-2 767 
for 90 min at 37°C, in the absence or presence of HRG (125 µg/ml), at different pH values. 768 
Cells were then washed, cultured for 3 days at pH 7.3, and infection was evaluated by 769 
determining the number of pfu/well. D-F Ect1/E6E7 (D), VK2/E6E7 (E) and HeLa cells 770 
(F)(80% confluence) were challenged with a pre-titered amount of HSV-1 derived 771 
amplicon vector encoding GFP, in the presence or absence of HRG (125 µg/ml), for 90 min 772 
at 37°C, at different pH values. Then, cells were washed, cultured for 3 days at pH 7.3, and 773 
infection was revealed by flow cytometry. Results are expressed as the mean ± SEM of 3-4 774 
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